SI-BONE, Inc. (SIBN): Price and Financial Metrics
SIBN Stock Summary
- SIBN's went public 2.52 years ago, making it older than merely 5.76% of listed US stocks we're tracking.
- SIBN's price/sales ratio is 15.52; that's higher than the P/S ratio of 87.45% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SIBN comes in at -11.98% -- higher than that of only 17.92% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to SI-BONE Inc, a group of peers worth examining would be ACRX, APYX, CDXC, ATEC, and IGC.
- Visit SIBN's SEC page to see the company's official filings. To visit the company's web site, go to si-bone.com.
SIBN Stock Price Chart Interactive Chart >
SIBN Price/Volume Stats
| Current price | $34.86 | 52-week high | $35.70 |
| Prev. close | $34.80 | 52-week low | $13.77 |
| Day low | $34.03 | Volume | 182,300 |
| Day high | $35.70 | Avg. volume | 293,643 |
| 50-day MA | $31.90 | Dividend yield | N/A |
| 200-day MA | $25.71 | Market Cap | 1.14B |
SI-BONE, Inc. (SIBN) Company Bio
SI-BONE, Inc. engages in the development of invasive surgical implant system. Its product, iFuse, seeks to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded on April 2008 by Mark A. Reiley and Jeffrey W. Dunn in and is headquartered in San Jose, CA.
Latest SIBN News From Around the Web
Below are the latest news stories about SI-BONE Inc that investors may wish to consider to help them evaluate SIBN as an investment opportunity.
SI-BONE appoints Anshul Maheshwari as CFOSI-BONE (SIBN) announces appointment Anshul Maheshwari as Chief Financial Officer ((CFO)) effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021.The appointment of Mr. Maheshwari completes the recent senior leadership transition which includes Laura Francis succeeding Jeff Dunn as... |
SI-BONE Appoints Anshul Maheshwari as Chief Financial Officer and Announces the Addition of Helen Loh and Laura Francis to the Board of DirectorsSANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company’s Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021. The appointment of Mr. Maheshwari completes the recently announced senior leadership transition which includes Laura Francis succeeding Jeff Dunn as Chief Executive Officer, and Tony Recupero becoming President, Commercial Operations. Jeff Dunn will remain with the company as Executive Chairman. “Anshul is an experienced finance executive with an impressive record of... |
Is SIBN Stock A Buy or Sell?In this article we will check out the progression of hedge fund sentiment towards SI-BONE, Inc. (NASDAQ:SIBN) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 […] |
How Much Of SI-BONE, Inc. (NASDAQ:SIBN) Do Institutions Own?Every investor in SI-BONE, Inc. ( NASDAQ:SIBN ) should be aware of the most powerful shareholder groups. Institutions... |
The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOsHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 18) AngioDynamics, Inc. (NASDAQ: ANGO ) Anixa Biosciences, Inc. (NASDAQ: ANIX ) ENDRA Life Sciences Inc. (NASDAQ: NDRA ) (announced a collaboration with Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA ) for NASH studies) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Neos Therapeutics, Inc. (NASDAQ: NEOS ) (reacted to the shareholder meeting held to vote on the proposal to merge with Aytu BioScience, Inc. (NASDAQ: AYTU )) NuVasive, Inc. (NASDAQ: NUVA ) SI-BONE, Inc. (NASDAQ: SIBN ) Sierra Oncology, Inc. (NASDAQ: SRRA ) Silverback Therapeutics, Inc. (NASDAQ: SBTX ) Terns Pharmaceuticals, Inc. (NASDAQ: TERN ) Varian Medical Systems, Inc. (NASDAQ: VAR ) Veric... |
SIBN Price Returns
| 1-mo | 15.78% |
| 3-mo | 11.73% |
| 6-mo | 57.17% |
| 1-year | 132.40% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 16.59% |
| 2020 | 39.07% |
| 2019 | 2.92% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching SIBN
Here are a few links from around the web to help you further your research on SI-BONE Inc's stock as an investment opportunity:SI-BONE Inc (SIBN) Stock Price | Nasdaq
SI-BONE Inc (SIBN) Stock Quote, History and News - Yahoo Finance
SI-BONE Inc (SIBN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...